November 2017November 2017
New Contraindications
Invirase (saquinavir) is now contraindicated with concomitant rilpivirine, dasatinib or sunitinib due to potentially life threatening cardiac arrhythmia, or lurasidone due to potentially serious and/or life threatening reactions.
Mersyndol and Panalgesic (paracetamol, codeine phosphate hemihydrate and doxylamine succinate) are now contraindicated in children younger than 12 years.
Mersyndol DayStrength, Panamax Co, Prodeine and Prodeinextra (paracetamol, codeine phosphate hemihydrate) are now contraindicated in children younger than 12 years.
Navelbine (vinorelbine tartrate) is now contraindicated with neutrophil count < 1500 cells/mm3, current or recent infection (within 2 weeks), platelet count < 100,000 cells/mm3, or use in combination with yellow fever vaccine.
Neulactil (periciazine) is now contraindicated with previous history of agranulocytosis, risk of urinary retention due to urethroprostatic disorders, children younger than 1 year (due to a possible link between use of phenothiazine containing products and sudden infant death syndrome), or in combination with dopaminergic antiparkinsonism agents.
Proctosedyl (cinchocaine hydrochloride, hydrocortisone) is now contraindicated in bacterial, fungal or parasitic infections.
Zomacton (somatropin (rbe)) treatment should be discontinued at renal transplantation in children with chronic renal disease.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au